Welcome to Peptineo. With an expanding portfolio of intellectual property and interdisciplinary technical expertise, Peptineo represents the new face of biotechnology and bioengineering. By employing a systems-based approach, Peptineo technical solutions involve drug delivery combinations including "tunable" nano-carriers, engineered peptides, re-formulated pharmaceuticals, and as appropriate, recombinant proteins. To that end, Peptineo is developing solutions that reflect research efforts in computer science, systems biology, physics, molecular biology, pharmacology, protein engineering and biotechnology. The employees of Peptineo believe that by having a broad range of technology and scientific expertise, Peptineo will have the resources required to efficiently address current or evolving clinical demands.
Can sugar save Pharma? Peptineo is working to commercialize a novel nanomaterial acetalated dextran (Ac-DEX) for drug delivery applications. This elegant technology was developed in the world famous lab of Jean Frechét, PhD. Subsequently, the technology continued to be developed by one of its key inventors Eric Bachelder, PhD - with breakthrough innovations employing the technology being led by Kristy Ainslie, PhD. Most notably, this technology was employed as part of the recent high profile DARPA vaccine challenge -which was targeted against an unknown pathogen. Peptineo is now working to demonstrate that the over US$10M invested in research & development of Ac-DEX has produced a disruptive, breakthrough solution for drug delivery challenges faced in modern medicine.
Acetalated Dextran for drug delivery applications. A brief video describing acetalated dextran(Ac-DEX), its development, and key drug delivery applications under development.
Current approaches to modern drug delivery ultimately fail because of unwanted side effects. Peptineo is working to develop solutions to address this key challenge for Pharma.